B


154 subjects screened
60 subjects randomized
Discontinued study: 8 (13.3%)
Adverse event 6 (10.0%)
Consent withdrawn 2 (3.3%)
Completed study: 52 (86.7%)
FAS / PD-PPS: 60 (100%)
PK-PPS**: 45 (75.0%)